Cardiology · Cardiac ultrasound guidance
Caption AI
GE HealthCare (Caption Health)
The first FDA-cleared AI sonographer-guidance system (De Novo DEN190040, February 2020), Caption AI demonstrated in a prospective multi-centre study that nurses with no prior echocardiography experience could obtain diagnostic-quality TTE views in 98.8 % of cases — a result published in JAMA Cardiology in 2021 and cited in every major point-of-care ultrasound review since. Acquired by GE HealthCare in February 2023 and now integrated across the Venue Family and Vscan Air SL platforms, Caption AI is the canonical example of an AI-startup regulatory breakthrough absorbed into an OEM distribution engine.
Performance Metrics
Clinical Evidence
The pivotal evidence base for Caption Guidance rests on the Narang et al. prospective multi-centre diagnostic study published in *JAMA Cardiology* in June 2021 (DOI 10.1001/jamacardio.2021.0185). Eight registered nurses with no prior echocardiography experience were recruited at Northwestern Memorial Hospital and Minneapolis Heart Institute at Allina Health. Each nurse scanned 30 patients (total n=240 paired scans), with each patient undergoing a paired study — nurse plus AI versus experienced registered diagnostic cardiac sonographer without AI. Five level-3 echocardiographers independently and blindly graded all acquisitions. Primary endpoints (diagnostic quality for LV size/function, RV size, and pericardial effusion) were met: *the AI-guided nurse studies were judged diagnostic in 237/240 cases for LV assessment (98.8 %)* and in 222/240 cases for RV size (92.5 %), with ≥92.5 % agreement between nurse and expert-sonographer reads on all primary assessments. This study formed the published clinical validation underpinning the De Novo authorization and the subsequent FDA Breakthrough Device designation recognition. The pivotal dataset for the original De Novo (n=240 scans, 8 nurses, minimal 1-hour didactic + 9 practice scans) pre-dated the published study; it was conducted at the same sites and is described in the FDA review document (DEN190040, February 2020). An expedited clearance of an updated Caption Guidance (announced May 2020) supported cardiac assessment of patients with COVID-19, with the FDA completing review in 25 days under pandemic-era prioritisation. A second 510(k) clearance (K200621, July 2020) covered an earlier version of the Caption Interpretation automated ejection-fraction software. A further clearance (K201992, September 2020) covered a performance update expanding guidance to 88 % more instruction types. Caption Interpretation AutoEF (K210747, January 2022) updated the automated LVEF estimation (AP4 + AP2 + PLAX) cleared as an interpretation companion to the guidance module. The evidence base is strong for image-acquisition quality in untrained hands — a genuine efficacy claim — but is limited to single-session prospective validation rather than a randomised controlled trial comparing clinical outcomes (hospitalisation, mortality, downstream testing) in AI- guided versus unguided populations. No peer-reviewed real-world outcome data have been published covering the post-GE integration period (2023–2026).
| Study | Design | n | Sensitivity | Specificity | AUC | Published |
|---|---|---|---|---|---|---|
| Narang A, Bae R, Hong H, et al. (Northwestern / Minneapolis HI) | ProspectiveProspective | 240 | 98.8% | — | — | JAMA Cardiology, Jun 2021 |
Clinical Pulse
Verified clinician sentiment
Verified clinician reviews launching · Apply to contribute →
Reviews are signed by clinicians verified against their regulator's public register.
Inside the Auris+ Listing
Six more sections complete this device’s Auris+ Listing.
Inside the algorithm
ProPro unlocks the five-stage editorial walkthrough of how this device's AI reaches a verdict — model architecture, training data, inference latency, and where the clinician stays in the loop.
Decision Ledger
ProPro unlocks a private, cross-vendor log of every case you read on this device — what the AI called, what you concluded, and a one-line reason if you overrode it. Ready for the EU AI Act's deployer logging obligations when they land in 2028.
Clinical Evidence Deep Dive
ProPro unlocks the structured clinical-evidence summary — study count, target patient population, and a tabular accuracy-metrics view drawn from peer-reviewed sources.
Peer-Reviewed Publications
ProPro unlocks the curated peer-reviewed publication list with PubMed cross-links — the citation backbone of every editorial verdict.
Post-Market & Regulatory Conditions
ProPro unlocks the post-market surveillance summary, recall record, and the conditions of approval that bound real-world use.
AI Algorithm Version History
ProPro unlocks the chronological record of algorithm version changes — what changed when, drawn from manufacturer changelogs and regulatory filings.
Regulatory Approvals
Class IIa
K210747
Class II
DEN190040
Class II
Safety Record
FDA Class 2 recall of Caption Interpretation Auto Ejection Fraction Software (recall ID 187913). Class 2 denotes remote probability of serious adverse consequences. Specific reason and scope are in the FDA recall database. The guidance module (Caption Guidance) was not subject to this recall.
A Class 2 device recall was issued by the FDA for Caption Interpretation Auto Ejection Fraction Software (FDA recall ID 187913). Class 2 indicates the probability of serious adverse health consequences is remote; the recall was a voluntary correction by Caption Health and does not indicate a Class 1 (life-threatening) failure mode. The specific technical reason for the recall and the scope of affected installations are on record in the FDA MAUDE/recall database but were not independently confirmed in published sources as of the review date. Clinicians relying on AutoEF measurements should verify LVEF against independent echocardiographic assessment in clinical-decision contexts. The guidance module (Caption Guidance) is a quality-meter and probe- direction overlay only — it does not modify images, alter device settings, or make diagnostic classifications — which substantially limits the harm surface for that component. No Caption Guidance-specific recalls or FDA safety communications have been identified in publicly available databases as of June 2026.
Intended Use & Indications
Caption AI (Caption Guidance™ + Caption Interpretation™ AutoEF) is a software-only SaMD that works as an accessory to compatible GE HealthCare diagnostic ultrasound systems (Venue Family POCUS; Vscan Air SL handheld). Caption Guidance provides real-time on-screen prompts — transducer orientation cues, probe-tilt vectors, and a dynamic Quality Meter — that replicate expert sonographer hand-off guidance across the standard 10-view TTE protocol (PLAX, PSAX, apical 2/4/5-chamber, subxiphoid). Caption Interpretation AutoEF then applies end-to-end deep learning to the acquired clips, automatically selects the highest-quality frames across AP4, AP2, and PLAX views, and returns an estimated left ventricular ejection fraction. Both components are decision-support tools; clinical diagnosis and treatment decisions remain with the supervising clinician. The device is indicated for adult patients in 2D-TTE settings, including point-of-care environments where specialist sonographers are unavailable.